title: Trilostane therapy for treatment of spontaneous hyperadrenocorticism in cats: 15 cases (2004-2012).
abstract: BACKGROUND
  Medical treatment with trilostane improves clinical signs, causes unclear insulin requirement changes, and variable survival times in cats.
  
  
  OBJECTIVE
  To characterize the long-term efficacy of trilostane in treating cats with hyperadrenocorticism (HAC).
  
  
  METHODS
  Fifteen client-owned cats with spontaneous HAC.
  
  
  METHODS
  Multicenter descriptive retrospective study with a search performed on all medical records for cats diagnosed with spontaneous HAC.
  
  
  RESULTS
  Clinical signs (13 of 15 cats) and ACTH stimulation testing results (13 of 15) improved with trilostane therapy. Diabetes mellitus was reported in 9/15 cases. Insulin requirements decreased by 36% within 2 months in 6/9 diabetic cats. Median survival time was 617 days for all cats (range 80-1,278 days). Complications included weight loss, urinary tract infections, chronic kidney disease, seizures, and recurrent pancreatitis. Hypocortisolemia was documented in 1 case. Cause of death occurred as a result of nonadrenal or nondiabetic illnesses (renal failure, seizures [caused by hypoglycemia or unknown]), or lymphoma.
  
  
  CONCLUSIONS
  Trilostane ameliorates clinical signs of HAC in cats, is tolerated well in the long term, and can lead to improved regulation of diabetes.
authors.affiliation: Section of Internal Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA.
authors.forename: A M
authors.initials: AM
authors.lastname: Mellett Keith
authors.forename: D
authors.initials: D
authors.lastname: Bruyette
authors.forename: S
authors.initials: S
authors.lastname: Stanley
mesh_terms: D000308:Adrenocortical Hyperfunction / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D000818:Animals; D001835:Body Weight / Q000502:physiology; D002371:Cat Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D002415:Cats; D003920:Diabetes Mellitus / Q000503:physiopathology / Q000662:veterinary*; D013196:Dihydrotestosterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D007328:Insulin / Q000008:administration & dosage; D008297:Male; D012189:Retrospective Studies; D014463:Ultrasonography
chemical_list: D004791:Enzyme Inhibitors; D007328:Insulin; D013196:Dihydrotestosterone; C009954:trilostane
keywords: Cushing's syndrome; Endocrinopathy; Feline; Steroid synthesis inhibitor